Loss of 700 million a year!

List of Heyu Biological R&D pipelines

Abbreviations: HCC = hepatocellular carcinoma; RMS = rhabdomyosarcoma; FGFRalt = FGFR mutation; UC = urothelial carcinoma; GC = gastric cancer; NSCLC = non-small cell lung cancer; TGCT = tendon sheath giant cell tumor; cGvHD = chronic graft versus host Disease; ALS = amyotrophic lateral sclerosis; TNBC = triple negative breast cancer; WHIM = warts, hypogammaglobulinemia, infection and bone marrow agranulocytosis

(Note: i.

Image source: Heyu Biological Prospectus

Image source: Heyu Biological Prospectus

Heyu Biology R&D team currently has about 90 members, more than 80% of the members have graduated degrees, and more than 30% of the members have doctoral degrees
.
Has 65 patents in 16 countries and regions (including Mainland China, Taiwan, Hong Kong, the United States, Japan, Canada, South Korea, the European Union, Australia, Russia, Brazil, Mexico, India, the Philippines, Israel and Singapore) (including those with global Rights licensing patents) and 108 patent applications
.

At the same time, a multi-dimensional discovery platform has been established, which can comprehensively conduct cancer genomics and screening, computational medicinal chemistry, transformation and biomarker science
.
The first-class R&D strength has attracted the favor of major capitals
.

It is reported that since its establishment, Heyu Bio has completed 5 rounds of financing, with a total financing amount of US$263 million; including the D-round financing of US$123 million in January this year
.
At present, Heyu Bio-Investors include Eli Lilly Asia Fund, Sinopharm Capital, CCB Capital, Taifu Capital, Qiming Venture Capital, Zhengxingu Capital, CICC Capital, Temasek, GIC, Warburg Pincus, Carlyle, Aobo Capital, Qingchi Capital and other well-known domestic and foreign institutions
.

In addition, Yu Biological has reached cooperation and licensing agreements with well-known biomedical and biological companies such as AstraZeneca and X4 Pharmaceuticals; it has reached a joint treatment development agreement with Junshi; it has reached a clinical supply agreement with Roche
.

Heyu Biology has the prospect of developing new and differentiated therapies for the treatment of cancer and other diseases to meet the urgent unmet needs of patients in China and around the world.
It is optimistic by all capitals, has broad development prospects, and has full R&D competitiveness
.
As its drug candidates enter the final stages of development, one or more drug candidates are expected to be commercialized in the next few years
.
This time, if the Hong Kong Stock Exchange is successfully listed, the establishment of a leading biopharmaceutical company will be further accelerated, and the development of the company will also take a step forward
.

Editor in charge: Sanqi